Thursday 12 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue: +14.0%
EPS: −277.9%
Free cash flow: −233.0%
Total debt: −10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%

Follow INCY

Alert me

Market cap: $24.9B
P/E: 58.1×
Fwd P/E: 57.3×
Dividend yield: —
F-score: 9/9
ROIC: 21.6%
Net debt / EBITDA: −2.2×
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Incyte Corporation (INCY) P/S ratio

Alert me on P/S ratio

As of 12 November 2026, Incyte Corporation (INCY) trades at a P/S ratio of 4.1×. Over the past ten years it has ranged from 2.4× (April 2025) to 36.5× (September 2015); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 9.1× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/INCY/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Incyte Corporation P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/INCY/metrics/ps-ratio">Incyte Corporation (INCY) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	3.8×	11.18%
FY2024	3.4×	(14.84%)
FY2023	4.0×	(23.87%)
FY2022	5.2×	(3.98%)
FY2021	5.4×	(23.83%)
FY2020	7.1×	(18.18%)
FY2019	8.7×	21.13%
FY2018	7.2×	(46.59%)
FY2017	13.4×	(22.72%)
FY2016	17.4×	(32.72%)

Period	P/S ratio	Change
Sep 2026	4.1×	5.13%
Jun 2026	3.9×	11.53%
Mar 2026	3.5×	(6.68%)
Dec 2025	3.8×	8.77%
43 more quarters	Free account

Against its own ten years

Low 2.4× High 36.5×

Ten-year median 7.3×

Current reading's percentile 29

Company	P/S ratio
JAZZ Jazz Pharmaceuticals PLC compare	3.3×
INCY Incyte Corporation	4.1×
ALNY Alnylam Pharmaceuticals, Inc. compare	4.2×
EXEL Exelixis, Inc. compare	6.9×
GMAB Genmab A/S Sponsored ADR compare	7.4×
BNTX BioNTech SE Sponsored ADR compare	7.8×
ASND Ascendis Pharma A/S compare	14.2×
INSM Insmed, Inc. compare	17.0×
ROIV Roivant Sciences Ltd. compare	704×
Biotechnology industry median	9.1×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Incyte Corporation (INCY) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on INCY

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on INCY

Stockrow Weekly